Ammonium tetrathiomolybdate

General information

Ammonium tetrathiomolybdate is a copper chelator that has been used to treat Wilson's disease [ ]. It also inhibits angiogenesis, perhaps by inhibiting copper ion-dependent membrane translocation involving a non-classical secretory pathway [ ], and inhibits NFκB [ ]. It has been used to treat advanced kidney cancer [ ] and metastatic cancer [ ]. Its most common adverse effects are anemia, neutropenia, leukopenia, and rises in aminotransferases, which generally resolve with either dosage adjustment or temporary withdrawal [ ].